Search

Bridgebio Pharma Inc

Open

SectorGezondheidszorg

84.95 3.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

82.02

Max

85.21

Belangrijke statistieken

By Trading Economics

Inkomsten

24M

-167M

Verkoop

40M

195M

EPS

-0.84

Winstmarge

-85.626

Werknemers

834

EBITDA

68M

-113M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+29.49% upside

Dividenden

By Acuity

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.4B

16B

Vorige openingsprijs

81.68

Vorige sluitingsprijs

84.95

Nieuwssentiment

By Acuity

43%

57%

109 / 340 Rangschikking in Healthcare

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 jul 2026, 23:51 UTC

News

Cavco Industries Inc. announced its first-quarter earnings release date, contributing to positive investor sentiment. Shares are higher in after-market trading.

23 jul 2026, 23:51 UTC

News

Scholastic Corp shares fell in after-market trading following fourth-quarter results, where revenue of $476.1 million missed expectations and net income dropped to $9.4 million.

23 jul 2026, 23:51 UTC

News
Social Media

Leidos Holdings shares are lower in after-market trading amid concerns over long-term revenue growth, despite a backlog of $48.37 billion.

23 jul 2026, 23:51 UTC

News

Codexis Inc announced a public offering of common stock, contributing to a notable decline in shares during after-market trading.

23 jul 2026, 23:51 UTC

News

PayPal shares are lower in after-market trading as Stripe and Advent assess acquisition options, with prior offers reportedly considered insufficient.

23 jul 2026, 23:46 UTC

News

Delek US Holdings Inc declared a quarterly dividend of $0.255 per share, contributing to shares trading higher in after-market hours.

23 jul 2026, 23:46 UTC

News
Social Media

CSX Corp shares rose in after-market trading following stronger-than-expected second-quarter results, with earnings of $0.54 per share and revenue of $3.94 billion.

23 jul 2026, 23:41 UTC

News
Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

23 jul 2026, 23:41 UTC

Event
News

GE Healthcare appointed George Newcomb as interim CFO and reported $5.30 billion in second-quarter revenue, with shares higher in after-market trading.

23 jul 2026, 23:41 UTC

News

Albertsons Companies reported revenue growth in Q1 2026, despite margin contraction. Shares are modestly higher in after-market trading since Thursday's close.

23 jul 2026, 23:41 UTC

News

Charter Communications launched a private offer to exchange notes, potentially issuing up to $1.75 billion in new notes, with shares trading higher in after-market hours.

23 jul 2026, 23:31 UTC

Social Media
Correlated Moves
News

Newmont Corporation's adjusted EPS of $2.10 missed estimates, with revenue at $6.12 billion, leading to a decline in after-market trading.

23 jul 2026, 23:31 UTC

News

Appian Corp's digital application update for community services workers supports over 210,000 and processed more than $100 million, boosting shares in after-market hours.

23 jul 2026, 23:26 UTC

News

Amgen Inc shares traded lower in after-market hours amid challenges in the biotechnology sector and increased credit risk perceptions in the investment-grade bond market.

23 jul 2026, 23:26 UTC

News

Hims & Hers Health Inc shares are higher after an FDA advisory panel recommended easing restrictions on a popular peptide and Canaccord reiterated a Buy rating.

23 jul 2026, 23:21 UTC

News

Robert Half shares are trading lower in after-market hours following a second-quarter revenue decline to $1.336 billion and a cautious outlook for Q3.

23 jul 2026, 23:21 UTC

Social Media
News

Maxlinear Inc's shares fell in after-hours trading following second-quarter results, with net revenue of $168.8 million but diluted earnings of $0.02 per share.

23 jul 2026, 23:21 UTC

News

McKesson Corp shares fell in after-market trading amid weakness in the Health Care Distributors sector, despite strong annual revenue and earnings growth.

23 jul 2026, 23:02 UTC

ETF Constituents
News

Vanguard Large-Cap ETF gains after hours, supported by major holdings like Microsoft and Tesla, despite broader market declines from new tariffs announced by President Trump.

23 jul 2026, 23:02 UTC

ETF Constituents
Social Media
News

Invesco QQQ Trust Series I rises in after-market trading, supported by positive sentiment from Intel's projected capital expenditures exceeding $20 billion.

23 jul 2026, 23:02 UTC

Social Media
News

RingCentral's revenue of $657 million surpassed estimates, prompting a raised full-year guidance. Shares are higher in after-market trading, rebounding from an earlier session low.

23 jul 2026, 23:02 UTC

Correlated Moves
News

Ovintiv Inc reported second-quarter earnings that missed expectations, with an EPS of $1.62. Shares are lower in after-market trading following the results.

23 jul 2026, 23:02 UTC

Social Media
News

Appfolio Inc shares are lower in after-market trading following second-quarter earnings. Revenue guidance of $1.117 billion to $1.127 billion fell short of expectations.

23 jul 2026, 23:02 UTC

News

Selective Insurance Group shares fell in after-hours trading following mixed second-quarter results, despite net income of $127.1 million and revenue of $1.39 billion.

23 jul 2026, 23:02 UTC

News
Social Media

Comfort Systems USA reported strong Q2 earnings and revenue, but shares are trading lower in after-market hours, indicating a shift in market sentiment.

23 jul 2026, 23:02 UTC

Social Media
News

Amkor Technology announced a $1.5 billion partnership with NVIDIA to enhance packaging capacity, boosting shares significantly in after-market hours.

23 jul 2026, 23:02 UTC

Correlated Moves
News

ServiceNow shares are higher in after-market hours as Macquarie raised its price target to $110, reflecting positive market sentiment and sector dynamics.

23 jul 2026, 23:02 UTC

Social Media
News

Intel Corp reported second-quarter revenue of $16.1 billion, exceeding expectations. The positive outlook has driven shares higher in after-market hours.

23 jul 2026, 23:02 UTC

News

Boeing Co shares are lower in after-market trading after announcing the divestiture of its stake in HRL Laboratories, LLC, amid broader market pressures.

23 jul 2026, 23:01 UTC

News
Social Media
Event

Tenet Healthcare Corp reported second-quarter adjusted EPS of $6.12, exceeding estimates. Shares are trading higher in after-market hours following strong earnings and raised guidance.

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

29.49% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 107.39 USD  29.49%

Hoogste 157 USD

Laagste 93 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

18

Buy

1

Hold

0

Sell

Sentiment

By Acuity

109 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
help-icon Live chat